RAMAT-GAN, Israel--(BUSINESS WIRE)--EarlySense Ltd., developer of ‘smart systems’ for monitoring changes in a patient’s clinical condition, announced today that it has received FDA clearance for its ES-16 system. The ES-16 system, cleared by the FDA, monitors heart and respiratory rates in both children and adults.
The technology developed by EarlySense utilizes a proprietary contact-free sensor, meaning that it is not physically connected to the body of the patient. The ES-16 System eliminates patient discomfort and enables the cost-effective monitoring of patients in settings such as homes, hospitals and other clinic settings such as long term care facilities. The system is currently being evaluated at several clinical settings on patients suffering from chronic diseases, such as Asthma, COPD and CHF, as well as at acute care facilities, on critical care patients and patients hospitalized for various medical and post-operative conditions.
